InflammX Therapeutics
PrivateLast Round
Series A
Jan 10, 2025
Total Funding Raised
$67.95M
Company Overview
InflammX Therapeutics is a clinical-stage biopharmaceutical company developing Xiflam, an orally administered small molecule to treat retinal diseases such as the dry form of age-related macular degeneration (AMD).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
InflammX Therapeutics Comparables
Compare InflammX Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AltRegen | 74% | |
| Belite Bio, Inc | 73% | |
| Alkeus Pharmaceuticals | 71% |
InflammX Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 10, 2025 | ||||
| Series B | Jul 24, 2012 | ||||
| Series A | Sep 25, 2008 |
InflammX Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RusnanoMedInvest | Series B |
| Domain Associates | Series B, Series A |
| GBS Venture Partners | Series B, Series A |
| BioPacificVentures | Series A, Series B |
| ExSight Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 22, 2026
Monthly visitors increased 375% MoM to 1.3K.
- Feb 1, 2026
Monthly visitors increased 175% MoM.
InflammX Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about InflammX Therapeutics's valuation, stock price, and market status.
Is InflammX Therapeutics a public or private company?
InflammX Therapeutics is a private company.
What is the current stock price of InflammX Therapeutics?
InflammX Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is InflammX Therapeutics worth (valuation)?
Valuation information for InflammX Therapeutics is not publicly available.
Can I buy InflammX Therapeutics stock?
InflammX Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was InflammX Therapeutics's last funding round?
InflammX Therapeutics's most recent funding round was Series A on January 10, 2025.
Who are the main investors in InflammX Therapeutics?
Key investors in InflammX Therapeutics include Domain Associates, GBS Venture Partners.
Will InflammX Therapeutics IPO soon?
No public IPO plans have been announced for InflammX Therapeutics.
How can I track InflammX Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor InflammX Therapeutics's secondary market activity and sign up for updates.